Studies have shown that stress-induced glucocorticoid surges and Tsc22d3 upregulation can interfere with treatment-induced immune surveillance and that glucocorticoid use after immune checkpoint inhibitors may alleviate lung-cancer-related symptoms (44). This evidence concerns the gene TSC22D3 and lung carcinoma.